|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Apc<sup>Min/+</sup></i> mice when infected with CR and <i>BLT1<sup>-/-</sup>;Apc<sup>Min/+</sup></i> mice, exhibited similar co-localization of p62 with LC3B and Dclk1 within the tumors.
|
31040926 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, autophagy markers LC3II/I (<i>p</i> < 0.05), Beclin-1 (<i>p</i> < 0.01), and P62 (<i>p</i> < 0.05) increased in the skeletal muscle of tumor-bearing mice.
|
30713500 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Also, the siRNA-MALAT-1 group had a decreased tumor volume and weight in the subcutaneous tumor xenograft model in nude mice, and increased LC3-II/LC3-I expression but decreased p62 expression in tumor tissues when compared with the blank group and the siNC group (all P<0.05).
|
28292022 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although recent empirical observations demonstrated that p62 is overexpressed in variety of human tumors, a mechanism of p62 overexpression is not known.
|
24121124 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a tumor-suppression mechanism, autophagy deficiency is common in tumors, which results in aberrant accumulation of p62 and activates p62-regulated pathways, such as activation of mTOR in nutrient sensing, and the activation of the Keap1-Nrf2 pathway for antioxidant stress, which are associated with cancer development.
|
31802896 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ATF4 upregulation by p62 deficiency in the stroma activates glucose carbon flux through a pyruvate carboxylase-asparagine synthase cascade that results in asparagine generation as a source of nitrogen for stroma and tumor epithelial proliferation.
|
28988820 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both the metastatic and recurrent tumor tissues expressed less p62 than the patient-matched primary tumor.
|
29699801 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By dividing patients into 2 levels of tumor expression of p62 c-myc, there was a trend for improved survival in patients with low expression (chi 2(1) = 3.65, p = 0.056).
|
2200214 |
1990 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correlation of quantitative dot blotting of tumour mRNA to flow cytometric p62 c-myc expression was good (r = 0.87, P less than 0.01).
|
1874294 |
1991 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Evidence has shown that p62 is upregulated in different cancers and promotes tumour growth, such as in liver cancer and lung cancer.
|
30793399 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further validation was done in vivo by conducting mouse tumor xenograft experiments, where HMGB1 knockdown tumors showed a significantly better (P < 0.001) response to radiotherapy and decreased autophagy (shown by P62 staining) as compared with controls.
|
26719575 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we investigated some mechanistic aspects of these effects.In mammary tumors bearing-dogs, i.m. injections of p62 plasmid reduced tumor sizes and their aggressive potential in 5 out of 6 animals, with one carcinoma switching to adenoma.
|
31754084 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High levels of p62 c-myc were associated with well differentiated tumours.
|
2679850 |
1989 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the role of p62 in tumour development depends on the interacting factors it recruits and its precise regulatory mechanism remains unclear.
|
30941888 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemically, c-myc p62 positive tumor cells were found in 24 cases (46.2%), while the stromal cells around the tumor cells showed c-myc p62 immunoreactivity in all cases (100%).
|
2188234 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry for the autophagy markers LC3B and p62 was applied on tumor tissue from 149 EAC patients treated with neoadjuvant chemotherapy, including pre- and post-therapeutic samples (62 matched pairs).
|
29897944 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo.
|
30275562 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In immunohistochemical analysis, AGG-treated tumor displays higher caspase 3 expression and less p62 and NRF2 expression in comparison to the control.
|
31715238 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In mice, p62 up-regulation promotes tumor cell growth and metastasis in a Twist1-dependent manner.
|
24927592 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we further demonstrated that QSOX1 null tumors present lower levels of the p62 protein.
|
24475161 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of LSD1 reduces both tumor growth and p62 protein degradation <i>in vivo</i>.
|
29088798 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistically, the Lmdd-MPFG vaccine activates the NF-κB pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway.
|
31659256 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Metabolic reprogramming of the tumor microenvironment by p62 and its partners.
|
29702207 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NF-κB Signaling Activation Induced by Chloroquine Requires Autophagosome, p62 Protein, and c-Jun N-terminal Kinase (JNK) Signaling and Promotes Tumor Cell Resistance.
|
28082672 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Not surprisingly, p62 is required for tumor transformation owing to its roles as a key molecule in nutrient sensing, as a regulator and substrate of autophagy, as an inducer of oxidative detoxifying proteins, and as a modulator of mitotic transit and genomic stability; all crucial events in the control of cell growth and cancer.
|
22424619 |
2012 |